Silk Road Medical, Inc
SILK · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.96 | -1.35 | 0.00 | 1.99 |
| FCF Yield | -0.41% | -2.27% | -1.86% | -1.22% |
| EV / EBITDA | -81.12 | -65.63 | -52.54 | -62.23 |
| Quality | ||||
| ROIC | -7.16% | -6.42% | -6.09% | -5.73% |
| Gross Margin | 75.15% | 75.28% | 73.62% | 72.88% |
| Cash Conversion Ratio | 0.20 | 1.08 | 0.65 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.80% | 19.96% | 20.41% | 21.67% |
| Free Cash Flow Growth | 72.39% | -76.40% | -24.89% | -41.21% |
| Safety | ||||
| Net Debt / EBITDA | -4.44 | -5.39 | -6.23 | -4.73 |
| Interest Coverage | -9.97 | -8.68 | -8.29 | -7.89 |
| Efficiency | ||||
| Inventory Turnover | 0.43 | 0.39 | 0.42 | 0.55 |
| Cash Conversion Cycle | 229.76 | 257.19 | 219.57 | 170.87 |